Management of nephropathic cystinosis

Bibliography

• Town M, Jean G, Cherqui S, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 1998;18:319-24
   PubMed Web of Science ®Google Scholar
• Touchman JW, Anikster Y, Dietrich NL, et al. The genomic region encompassing the nephropathic cystinosis gene (CTNS): complete sequencing of a 200-kb segment and discovery of a novel gene within the common cystinosis-causing deletion. Genome Res 2000;10:165-73
   PubMed Web of Science ®Google Scholar
• Wamelink MM, Struys EA, Jansen EE, et al. Sedoheptulokinase deficiency due to a 57-kb deletion in cy stinosis patients causes urinary accumulation of sedoheptulose: elucidation of the CARKL gene. Hum Mutat 2008;29:532-6
   PubMed Web of Science ®Google Scholar
• Freed KA, Blangero J, Howard T, et al. The 57 kb deletion in cystinosis patients extends into TRPV1 causing dysregulation of transcription in peripheral blood mononuclear cells. J Med Genet 2011;48:563-6
   PubMed Web of Science ®Google Scholar
• Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med 2002;347:111-21
   PubMed Web of Science ®Google Scholar
• Chan AM, Lynch MJ, Bailey JD, et al. Hypothyroidism in cystinosis. A clinical, endocrinologic and histologic study involving sixteen patients with cystinosis. Am J Med 1970;48:678-92
   PubMed Web of Science ®Google Scholar
• Chik CL, Friedman A, Merriam GR, et al. Pituitary-testicular function in nephropathic cystinosis. Ann Intern Med 1993;119:568-75
   PubMed Web of Science ®Google Scholar
• Fivush B, Flick JA, Gahl WA. Pancreatic exocrine insufficiency in a patient with nephropathic cystinosis. J Pediatr 1988;112:49-51
   PubMed Web of Science ®Google Scholar
• Fivush B, Green OC, Porter CC, et al. Pancreatic endocrine insufficiency in posttransplant cystinosis. Am J Dis Child 1987;141:1087-9
   PubMedGoogle Scholar
• Broyer M, Tete MJ, Guest G, et al. Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine. J Inherit Metab Dis 1996;19:65-75
   PubMed Web of Science ®Google Scholar
• Besouw MT, Kremer JA, Janssen MC, et al. Fertility status in male cystinosis patients treated with cysteamine. Fertil Steril 2010;93:1880-3
   PubMed Web of Science ®Google Scholar
• Gahl WA, Bernardini I, Dalakas M, et al. Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 1988;81:549-60
   PubMed Web of Science ®Google Scholar
• Besouw MT, Schneider J, Janssen MC, et al. Copper deficiency in patients with cystinosis with cysteamine toxicity. J Pediatr 2013;163:754-60
   PubMed Web of Science ®Google Scholar
• Usberti M, Pecoraro C, Federico S, et al. Mechanism of action of indomethacin in tubular defects. Pediatrics 1985;75:501-7
   PubMed Web of Science ®Google Scholar
• Imanishi M, Yoshioka K, Okumura M, et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int 1997;63:S198-200
   Google Scholar
• Abitbol C, Foreman JW, Strife CF, et al. Quantitation of growth deficits in children with renal diseases. Semin Nephrol 1989;9:31-6
   PubMed Web of Science ®Google Scholar
• Wuhl E, Haffner D, Offner G, et al. Long-term treatment with growth hormone in short children with nephropathic cystinosis. J Pediatr 2001;138:880-7
   PubMed Web of Science ®Google Scholar
• Thoene JG, Oshima RG, Crawhall JC, et al. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest 1976;58:180-9
   PubMed Web of Science ®Google Scholar
• Gahl WA, Tietze F, Butler JD, et al. Cysteamine depletes cystinotic leucocyte granular fractions of cystine by the mechanism of disulphide interchange. Biochem J 1985;228:545-50
   PubMed Web of Science ®Google Scholar
• Jézégou A, Llinares E, Anne C, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA 2012;109:E3434-43
   Web of Science ®Google Scholar
• Levtchenko E, De-Graaf-Hess A, Wilmer M, et al. Comparison of cystine determination in mixed leukocytes vs polymorphonuclear leukocytes for diagnosis of cystinosis and monitoring of cysteamine therapy. Clin Chem 2004;50:1686-8
   PubMed Web of Science ®Google Scholar
• Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 1993;328:1157-62
   PubMed Web of Science ®Google Scholar
• Gahl WA, Reed GF, Thoene JG, et al. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med 1987;316:971-7
   PubMed Web of Science ®Google Scholar
• Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med 2007;147:242-50
   PubMed Web of Science ®Google Scholar
• Van Stralen KJ, Emma F, Jager KJ, et al. Improvement in the renal prognosis in nephropathic cystinosis. Clin J Am Soc Nephrol 2011;6:2485-91
   PubMed Web of Science ®Google Scholar
• Brodin-Sartorius A, Tete MJ, Niaudet P, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 2012;81:179-89
   PubMed Web of Science ®Google Scholar
• Besouw M, Levtchenko E. Growth retardation in children with cystinosis. Minerva Pediatr 2010;62:307-14
   PubMed Web of Science ®Google Scholar
• Kimonis VE, Troendle J, Rose SR, et al. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 1995;80:3257-61
   PubMed Web of Science ®Google Scholar
• Corden BJ, Schulman JD, Schneider JA, et al. Adverse reactions to oral cysteamine use in nephropathic cystinosis. Dev Pharmacol Ther 1981;3:25-30
   PubMedGoogle Scholar
• Dohil R, Newbury RO, Sellers ZM, et al. The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 2003;143:224-30
   PubMed Web of Science ®Google Scholar
• Dohil R, Fidler M, Barshop B, et al. Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005;20:1786-93
   PubMed Web of Science ®Google Scholar
• Besouw M, Blom H, Tangerman A, et al. The origin of halitosis in cystinotic patients due to cysteamine treatment. Mol Genet Metab 2007;91:228-33
   PubMed Web of Science ®Google Scholar
• Besouw MT, Bowker R, Dutertre JP, et al. Cysteamine toxicity in patients with cystinosis. J Pediatr 2011;159:1004-11
   PubMed Web of Science ®Google Scholar
• Besouw M, Van den Heuvel L, Van Eijsden R, et al. Increased human dermal microvascular endothelial cell survival induced by cysteamine. J Inherit Metab Dis 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Cantani A, Giardini O, Ciarnella CA. Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes. Am J Ophthalmol 1983;95:713-14
   PubMed Web of Science ®Google Scholar
• Belldina EB, Huang MY, Schneider JA, et al. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin Pharmacol 2003;56:520-5
   PubMed Web of Science ®Google Scholar
• Fidler MC, Barshop BA, Gangoiti JA, et al. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion. Br J Clin Pharmacol 2007;63:36-40
   PubMed Web of Science ®Google Scholar
• Dohil R, Fidler M, Gangoiti JA, et al. Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 2010;156:71-5
   PubMed Web of Science ®Google Scholar
• Langman CB, Greenbaum LA, Sarwal M, et al. Effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol 2013;7:1112-20
   Web of Science ®Google Scholar
• McCaughan B, Kay G, Knott RM, et al. A potential new prodrug for the treatment of cystinotis: design, synthesis and in-vitro evaluation. Bioorg Med Chem Lett 2008;18:1716-19
   PubMed Web of Science ®Google Scholar
• Omran Z, Kay G, Di Salvo A, et al. PEGylated derivates of cystamine as enhanced treatments for nephropathic cystinosis. Bioorg Med Chem Lett 2011;21:45-7
   PubMed Web of Science ®Google Scholar
• Omran Z, Moloney KA, Benylles A, et al. Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis. Bioorg Med Chem 2011;19:3492-6
   PubMed Web of Science ®Google Scholar
• Omran Z, Kay G, Hector EE, et al. Folate pro-drug of cystamine as enhanced treatment of nephropathic cystinosis. Bioorg Med Chem Lett 2011;21:2502-4
   PubMed Web of Science ®Google Scholar
• Syres K, Harisson F, Tadlock M, et al. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood 2009;114:2542-52
   PubMed Web of Science ®Google Scholar
• Yeagy BA, Harrison F, Gubler MC, et al. Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int 2011;79:1198-206
   PubMed Web of Science ®Google Scholar
• Harrison F, Yeagy BA, Rocca CJ, et al. Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis. Mol Ther 2013;21:433-44
   PubMed Web of Science ®Google Scholar
• Kleta R, Bernardini I, Ueda M, et al. Long-term follow-up of well-treated nephropathic cystinosis patients. J Pediatr 2004;145:555-60
   PubMed Web of Science ®Google Scholar
• Jackson M, Young E. Prenatal diagnosis of cystinosis by quantitative measurement of cystine in chorionic villi and cultured cells. Prenat Diagn 2005;25:1045-7
   PubMed Web of Science ®Google Scholar
• Wamelink MM, Struys EA, Jansen EE, et al. Elevated concentrations of sedoheptulose in bloodspots of patients with cystinosis caused by the 57-kb deletion: implications for diagnostics and neonatal screening. Mol Genet Metab 2011;102:339-42
   PubMed Web of Science ®Google Scholar
• Levtchenko EN, van Dael CM, de Graaf-Hess AC, et al. Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 2006;21:110-13
   PubMed Web of Science ®Google Scholar
• Besouw M, Tangerman A, Cornelissen E, et al. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate. Mol Genet Metab 2012;107:234-6
   PubMed Web of Science ®Google Scholar
• Baum M. The Fanconi syndrome of cystinosis: insights into the pathophysiology. Pediatr Nephrol 1998;12:492-7
   PubMed Web of Science ®Google Scholar
• Levtchenko E, de Graaf-Hess A, Wilmer M, et al. Altered status of glutathione and its metabolites in cystinotic cells. Nephrol Dial Transplant 2005;20:1828-32
   PubMed Web of Science ®Google Scholar
• Wilmer MJ, de Graaf-Hess A, Blom HJ, et al. Elevated oxidized glutathione in cystinotic proximal tubular epithelial cells. Biochem Biophys Res Commun 2005;337:610-14
   PubMed Web of Science ®Google Scholar
• Laube GF, Shah V, Stewart VC, et al. Glutathione depletion and increased apoptosis rate in human cystinotic proximal tubular cells. Pediatr Nephrol 2006;21:503-9
   PubMed Web of Science ®Google Scholar
• Mannucci L, Pastore A, Rizzo C, et al. Impaired activity of the gamma-glutamyl cycle in nephropathic cystinosis fibroblasts. Pediatr Res 2006;59:332-5
   PubMed Web of Science ®Google Scholar
• Park M, Helip-Wooley A, Thoene J. Lysosomal cystine storage augments apoptosis in cultured human fibroblasts and renal tubular epithelial cells. J Am Soc Nephrol 2002;13:2878-87
   PubMed Web of Science ®Google Scholar
• Park MA, Pejovic V, Kerisit KG, et al. Increased apoptosis in cystinotic fibroblasts and renal proximal tubule epithelial cells results from cysteinylation of protein kinase C delta. J Am Soc Nephrol 2006;17:3167-75
   PubMed Web of Science ®Google Scholar
• Sansanwal P, Yen B, Gahl WA, et al. Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis. J Am Soc Nephrol 2010;21:272-83
   PubMed Web of Science ®Google Scholar
• Sansanwal P, Sarwal MM. p62/SQSTM1 prominently accumulates in renal proximal tubules in nephropathic cystinosis. Pediatr Nephrol 2012;27:2137-44
   PubMed Web of Science ®Google Scholar
• Johnson JL, Napolitano G, Monfregola J, et al. Upregulation of the rab27a-dependent trafficking and secretory mechanisms improves lysosomal transport, alleviates endoplasmic reticulum stress, and reduces lysosome overload in cystinosis. Mol Cell Biol 2013;33:2950-62
   PubMed Web of Science ®Google Scholar
• Iglesias DM, El-Kares R, Taranta A, et al. Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulation in vitro. PLoS One 2012;7:e42840
   PubMed Web of Science ®Google Scholar
• Taranta A, Petrini S, Palma A, et al. Identification and subcellular localization of a new cystinosin isoform. Am J Physiol Renal Physiol 2008;294:F1101-8
   Web of Science ®Google Scholar